Overview
- Roszdravnadzor said it is verifying media claims that patients in at least eight regions cannot obtain continuous glucose monitoring sensors.
- The regulator stated that regional funding for CGM procurement is provided on time, production is increasing, and device quality and availability are under oversight.
- Bashkortostan’s Health Ministry rejected reports of disruptions, saying all children are fully supplied and warehouse reserves cover needs through June 2026 with support from a state pharmacy network.
- Under the national project, CGM systems are budget-funded for all children with type 1 diabetes and, since 2025, for pregnant women, with more than 61,000 children and over 53,000 pregnant women supplied this year.
- Roszdravnadzor noted 11 CGM systems and 72 insulin drugs are registered in Russia, reported stable insulin supplies, and urged patients to report any local interruptions.